C9293: Injection, glucarpidase, 10 units
C9293 is a HCPCS Level II code for injection, glucarpidase, 10 units. It belongs to the Outpatient Prospective Payment System section. Whether Medicare pays it depends on the coverage rule below.
Medicare coverage: Special coverage instructions apply
There are published conditions attached to this code. Check the applicable coverage policy before billing it: the code being valid is not the same as the service being covered.
From the coverage field of the CMS Alpha-Numeric HCPCS File, release 2026Q4-Oct. This states Medicare’s position on the code, not on your particular claim.
Medically Unlikely Edits: units per day
The most units of C9293 Medicare will pay on one date of service. Bill more on a single line and it is denied. The limit is not the same in every setting, so the row that matters is the one matching the claim you are building.
- practitioner
- 700 units MAI 3: Date of Service Edit: Clinical · Prescribing Information
- outpatient
- 700 units MAI 3: Date of Service Edit: Clinical · Prescribing Information
The adjudication indicator decides whether exceeding the limit is worth appealing at all: MAI 1 is a line edit you can support with documentation, MAI 3 is a date-of-service edit that is also appealable, and MAI 2 is absolute, no documentation overrides it. CMS MUE 2026Q4.
The CMS record for C9293
- Long descriptor
- Injection, glucarpidase, 10 units
- Short descriptor
- Injection, glucarpidase
- Added
- October 1, 2012
- BETOS
- O1E
- Pricing indicator
- 53: Other
The official wording. This is what the code means.
CMS's 28-character form, which is what shows up on a remittance advice.
When CMS introduced the code.
Berenson-Eggers Type of Service: CMS's own analytic grouping.
Statute.
Codes adjacent to C9293
HCPCS has no hierarchy: related items simply sit next to each other in the numbering. If C9293 is not quite right, the correct code is very often within a few positions of it.
- C9176Tc-99m from domestically produced non-heu mo-99, [minimum 50 percent], full cost recovery add-on, per study dose
- C9248Injection, clevidipine butyrate, 1 mgterminated
- C9250Human plasma fibrin sealant, vapor-heated, solvent-detergent (artiss), 2 ml
- C9254Injection, lacosamide, 1 mg
- C9257Injection, bevacizumab, 0.25 mg
- C9275Injection, hexaminolevulinate hydrochloride, 100 mg, per study doseterminated
- C9285Lidocaine 70 mg/tetracaine 70 mg, per patch
- C9290Injection, bupivacaine liposome, 1 mgterminated
- C9300Injection, indigotindisulfonate sodium, 1 mgterminated
- C9301Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic doseterminated
- C9302Injection, zanidatamab-hrii, 2 mgterminated
- C9303Injection, zolbetuximab-clzb, 1 mgterminated
- C9304Injection, marstacimab-hncq, 0.5 mgterminated
- C9305Injection, nipocalimab-aahu, 3 mgterminated
- C9306Injection, telisotuzumab vedotin-tllv, 1 mgterminated
- C9307Injection, linvoseltamab-gcpt, 1 mgterminated